BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...
TransCode’s RIG-I agonist precursor comprises single-stranded 5’-uncapped biphosphate or triphosphate oligonucleotides having a sequence complementary to an endogenous microRNA. The precursor may be ...
Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its public offering. Our government trade tracker caught Pelosi’s 169% AI winner.
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday. Separately, ...
Patients currently remain on study for continued treatment with TTX-MC138 No significant safety or dose limiting toxicities reported TTX-MC138, an antisense oligonucleotide conjugated to TransCode’s ...
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Friday. Separately, HC Wainwright ...
BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, ...
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback